Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
14 févr. 2024 08h45 HE
|
Silo Pharma, Inc.
Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE)...
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
01 févr. 2024 10h00 HE
|
Silo Pharma, Inc.
Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 01,...
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
24 janv. 2024 08h55 HE
|
Silo Pharma, Inc.
Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety. SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO)...
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
04 janv. 2024 08h55 HE
|
Silo Pharma, Inc.
Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage...
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
28 déc. 2023 08h25 HE
|
Silo Pharma, Inc.
Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the...
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
21 nov. 2023 08h01 HE
|
Silo Pharma, Inc.
MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia ...
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
08 nov. 2023 08h11 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
16 oct. 2023 08h11 HE
|
Silo Pharma, Inc.
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
11 oct. 2023 08h35 HE
|
Silo Pharma, Inc.
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the...
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
20 sept. 2023 08h28 HE
|
Silo Pharma, Inc.
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...